Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK migraine combo is Trexima

Executive Summary

GlaxoSmithKline/Pozen's acute migraine therapy combining Imitrex and naproxen will be marketed under the proposed brand name Trexima. Companies have commenced Phase III studies on the sumatriptan/naproxen fixed-dose combination and expect to submit an NDA in the second half of 2005. GSK and Pozen signed the development agreement in June 2003...

You may also be interested in...

Pozen Migraine Combo “Not Approvable”; Imitrex Combo Could Be Affected

FDA's "not approvable" letter for Pozen's naproxen/ metoclopramide migraine combination MT-100 may prompt the company to revisit the Phase III trial design for an Imitrex combo under development with GlaxoSmithKline

Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty

The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts